ClinicalTrials.gg
RecruitingNCT06287528Updated Feb 10, 2026

A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)

A Phase 1 interventional study of 19-28z/IL-18 CAR T cells in Philadelphia-Negative ALL, Philadelphia-Positive ALL and Relapsed ALL, Adult, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
17 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Memorial Sloan Kettering Cancer Center — 4 open to participants now, 11 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Memorial Sloan Kettering Cancer Center.

Planned enrollment
20th of 29
18 · median 29
Started
2024
the only one that year
Phase 1
19 of 46
1 open now
Primary completion
2028-02
later than 6 of 10 live
Registered
43rd of 46
by date

Among the 46 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Memorial Sloan Kettering Cancer Center, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2024, is one of 19 in phase 1, reaches primary completion later than 6 of the 10 other live ones, and was the 43rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

4 of the 46 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 17 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory to be changed (modified) to become 19-28z/IL-18, the CAR T-cell therapy that participants will receive during the study. Making the participants' study therapy will take about 2-4 weeks.

03

Conditions studied

  • Philadelphia-Negative ALL
  • Philadelphia-Positive ALL
  • Relapsed ALL, Adult
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia (ALL)
  • Refractory Acute Lymphoid Leukemia in Relapse

Keywords

  • Philadelphia-Negative ALL
  • Philadelphia-Positive ALL
  • Philadelphia chromosome negative (Ph-negative) B-ALL
  • Philadelphia chromosome positive (Ph+ positive) B-ALL
  • Relapsed ALL, Adult
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia (ALL)
  • Refractory Acute Lymphoid Leukemia in Relapse
  • 19-28z/IL-18
  • 23-307
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
17 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have R/R ALL meeting one of the following criteria:
  • For Philadelphia chromosome (Ph) negative B-ALL: or relapsed disease to at least 1 prior multiagent systemic chemotherapy regimen that included both induction and consolidation therapy
  • For Philadelphia chromosome (Ph) positive B-ALL: patients must have exhibited persistent or progressive disease following at least 1 prior second- or third-generation tyrosine kinase inhibitor
  • Signed form (ICF) prior to any study procedures
  • Age: The first 3 patients enrolled into the study will be ≥ 17 years of age at time of enrollment. If a DLT is observed, the additional 3 patients in this cohort will also be ≥ 17 years of age. Additional patients will be ≥12 years of age at time of enrollment.
  • Documentation of CD19 positivity on leukemia blasts if prior anti-CD19 treatment
  • History of prior hematopoietic stem cell transplant (HSCT) is allowed if ≥3 months from time of enrollment and no evidence of acute or chronic (GVHD) within 4 weeks prior to enrollment
  • Donor lymphocyte infusions (DLI) permitted if ≥4 weeks prior to leukapheresis
  • History of secondary CNS or meningeal involvement allowed if:

    • cannot be the only site of disease
    • absence of neurologic symptoms, such as: seizures, stroke-like deficits, altered mental status, aphasia, or psychosis
  • Adequate organ function at time of screening, including:

    • or AST ≤5x and total ≤2 (or ≤3 if history of Gilbert's syndrome or leukemic infiltration of the liver)
    • Serum creatinine \<2.0mg/100mL
    • SaO2 ≥92% on room air
    • (LVEF) ≥50% within 1 month of screening
  • performance status 0-1 or Lansky performance status ≥ 60 for patients \< 16 years old
  • Prior CD19-targeted therapies (including CD19 CAR-T cell and CD19 bispecific T-cell engagers) are allowed including anti-CD19 CAR T therapy, as long as CD19 positivity is confirmed on most recent bone marrow, blood or tumor

Exclusion criteria

Exclusion Criteria:

  • Concurrent active excluding: nonmelanoma skin cancer or localized solid tumor that has undergone definitive therapy and with low risk of recurrence, e.g., prostate, breast
  • Burkitt's leukemia or lymphoma or CML in lymphoid blast crisis
  • Radiologically detected or symptomatic CNS disease or CNS 3 disease (i.e., presence of ≥5/µL WBCs in CSF). Subjects with adequately treated CNS leukemia are eligible.
  • The following medications are excluded:

    • : Therapeutic doses of corticosteroids (greater than 10mg daily of prednisone or its equivalent) within 7 days of leukapheresis or 72 hours prior to CAR T cell infusion.
    • Chemotherapy: Systemic chemotherapy should be stopped one week prior to leukapheresis or starting CAR T cell infusion or lymphodepleting chemotherapy. Hydroxyurea for cytoreduction can be administered up to 72 hours before leukapheresis or CAR T cell infusion.
  • History of class III-IV (NYHA) heart failure, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other cardiac condition within 6 months of screening
  • Patients with history of significant disease and/or inflammatory condition affecting the CNS are ineligible
  • Systemic treatment for within 4 weeks prior to enrollment
  • Patients with known severe autoimmune disease (e.g., Crohn's, rheumatoid arthritis, or lupus) that in the investigator's opinion has high likelihood of requiring systemic immune suppressive medications
  • Patients with infection
  • Patients with active infection (as manifested by either detectable hepatitis B virus DNA by PCR and/or positivity for hepatitis B surface antigen)
  • Patients with active infection (as manifested by detectable hepatitis C virus RNA by PCR)
  • Patients with uncontrolled systemic fungal, bacterial, viral or other infection including COVID-19 at time of leukapheresis or at time of CAR T cell infusion.
  • Other uncontrolled medical or psychological conditions as well as social or logistical issues that may interfere with compliance with the protocol, as determined by the investigator
  • Treatment with live, attenuated vaccine \<4 weeks prior to leukapheresis
  • Pregnant or lactating/breastfeeding women
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    0.5x106 CAR-T cell/kg without lymphodepleting chemotherapy (LDC)

    Biological: 19-28z/IL-18 CAR T cells

  • Experimental
    Dose Level 2

    0.5x106 cells/kg with lymphodepleting chemotherapy (LDC)

    Biological: 19-28z/IL-18 CAR T cells

  • Experimental
    Dose Level 3

    1x106 cells/kg with lymphodepleting chemotherapy (LDC)

    Biological: 19-28z/IL-18 CAR T cells

Interventions

  • Biological19-28z/IL-18 CAR T cells

    19-28z/IL-18 CAR T cells are an investigational new drug (IND) for the treatment of R/R B-ALL

06

What researchers measure

Primary outcomes

  1. Toxicity as determined by CTCAE, version 5.0

    The primary objective is to determine the safety of 19-28z/IL18 CAR T cells in patients with R/R ALL. Toxicity will be graded on a scale of 1 to 5 as described by the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: 4 weeks

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Cancer Suffolk-Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
    Uniondale, New York 11553, United States
    Recruiting
    • Jae Park, MD · Contact646-608-3743
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 48 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2024
First posted
Mar 1, 2024
StartActual
Feb 23, 2024
Primary completionEst.
Feb 23, 2028
CompletionEst.
Feb 23, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06287528
Responsible party
Sponsor
First posted
Mar 1, 2024
Start date
Feb 23, 2024
Primary completion
Feb 23, 2028 (estimated)
Completion
Feb 23, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Jae Park, MD
Contact
parkj6@mskcc.org
646-608-3743
Mark Geyer, MD
Contact
geyerm@mskcc.org
646-608-3745
Jae Park, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion